Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Urinary Bladder Neoplasms 1Solid Tumor 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1NSCLC 1Myeloproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Head and Neck Neoplasms 1Glioblastoma 1Bone Marrow Diseases 1Advanced Solid Tumor 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 48fludarabine phosphate 45fludarabine 38Whole-Body Irradiation 38Mycophenolic Acid 37Imatinib Mesylate 36nilotinib 34Tacrolimus 30Busulfan 23Cyclosporine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17Dasatinib 17thymoglobulin 16Methotrexate 16Thiotepa 15Peripheral Blood Stem Cell Transplantation 15Antilymphocyte Serum 15bosutinib 13Filgrastim 13Stem Cell Transplantation 11sargramostim 8ponatinib 8Cytarabine 8Cyclosporins 8Cord Blood Stem Cell Transplantation 8Clofarabine 8Sirolimus 7Rituximab 7plerixafor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × BID protein, human × Clear all
NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Novartis

Phase 3 Completed
199 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02627677 2021-11-26

OPTIC-2L

Takeda

Phase 3 Terminated
44 enrolled 22 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡